US 11,993,634 B2
Recombinant varicella-zoster virus (VZV) vaccine
Jian Kong, Beijing (CN); Pei Hong Jiang, Beijing (CN); Ling Peng, Beijing (CN); Shuai Yang, Beijing (CN); Leitao Xu, Beijing (CN); and Kun Zhang, Beijing (CN)
Assigned to BEIJING LUZHU BIOTECHNOLOGY CO., LTD., Beijing (CN)
Appl. No. 17/422,835
Filed by BEIJING LUZHU BIOTECHNOLOGY CO., LTD., Beijing (CN)
PCT Filed May 14, 2020, PCT No. PCT/CN2020/090200
§ 371(c)(1), (2) Date Jul. 14, 2021,
PCT Pub. No. WO2021/103434, PCT Pub. Date Jun. 3, 2021.
Claims priority of application No. 201911203663.2 (CN), filed on Nov. 29, 2019.
Prior Publication US 2022/0363721 A1, Nov. 17, 2022
Int. Cl. C07K 14/005 (2006.01); A61K 9/19 (2006.01); A61K 39/25 (2006.01); A61K 39/39 (2006.01); A61P 31/22 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 9/19 (2013.01); A61K 39/25 (2013.01); A61K 39/39 (2013.01); A61P 31/22 (2018.01); A61K 2039/5254 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/6056 (2013.01); C07K 2319/30 (2013.01); C12N 2710/16722 (2013.01); C12N 2710/16734 (2013.01)] 10 Claims
 
1. A recombinant varicella-zoster virus (VZV) vaccine preparation, comprising a fusion protein formed by an amino acid sequence of an extracellular domain of a recombinant glycoprotein gE of a live attenuated VZV strain (OKA strain) gene and an Fc fragment of human immunoglobulin, wherein the fusion protein has an amino acid sequence shown in SEQ ID No. 1.